Patents Assigned to Takeda Pharmaceuticals U.S.A., Inc.
  • USE OF MARIBAVIR IN TREATMENT REGIMENS
    Publication number: 20240156849
    Abstract: Characterization of drug-drug interaction properties and pharmacological properties of maribavir is useful to inform potential drug-drug interactions and dosing strategies when administering with co-medications.
    Type: Application
    Filed: December 29, 2023
    Publication date: May 16, 2024
    Applicants: Takeda Pharmaceuticals U.S.A., Inc, Certara USA, Inc.
    Inventors: Heng Song, Kefeng Sun, Matthew Crouthamel, Grace Chen, Andy Z.X. Zhu, Ingrid Nicolle Michon, Howard James Burt, Zoe Elizabeth Barter, Sibylle Neuhoff
  • METHODS OF TREATMENT AND COMPOSITIONS WITH XANTHINE OXIDASE INHIBITORS
    Publication number: 20180311217
    Abstract: Methods and pharmaceutical compositions for reducing number of gout flares experienced by a patient are disclosed. The methods can comprise administering to a patient with hyperuricemia an effective amount of a xanthine oxidase inhibitor in a modified release dosage form once daily or in an immediate release dosage form two or more times daily to prevent at least one gout flare or reduce the number of gout flares experienced by the patient.
    Type: Application
    Filed: December 1, 2017
    Publication date: November 1, 2018
    Applicants: Takeda Pharmaceuticals U.S.A., Inc., Teijin Pharma Limied
    Inventors: Lhanoo Gunawardhana, Vijay Gupte, Himanshu Naik, Michael Mayer, Kanji Komatsu
  • Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
    Patent number: 9937157
    Abstract: The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: April 10, 2018
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Vijay Gupte, Majid Vakilynejad
  • Multiple PPI dosage form
    Patent number: 9889152
    Abstract: Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: February 13, 2018
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Majid Vakilynejad
  • Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
    Patent number: 9889125
    Abstract: The present invention relates to methods of treating heartburn in a patient receiving clopidogrel therapy. In another aspect, the present invention relates to methods of preventing gastric bleeding or hemorrhage in patients receiving clopidogrel therapy.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: February 13, 2018
    Assignee: TAKEDA PHARMACEUTICALS U.S.A., INC.
    Inventor: Ronald D. Lee
  • NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS
    Publication number: 20160317505
    Abstract: The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors.
    Type: Application
    Filed: January 29, 2016
    Publication date: November 3, 2016
    Applicant: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Vijay Gupte, Majid Vakilynejad
  • Colchicine solid-state forms; methods of making; and methods of use thereof
    Patent number: 9255063
    Abstract: Disclosed are new colchicine solid-state forms, methods of preparing the solid-state forms, as well as formulations prepared therefrom and uses thereof.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: February 9, 2016
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Tong Sun, Kurt Nielsen, Shawn Watson, Rolf Hilfiker, Andreas Sieber
  • Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
    Patent number: 9248119
    Abstract: The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: February 2, 2016
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Vijay Gupte, Majid Vakilynejad
  • Multiple PPI dosage form
    Patent number: 9238029
    Abstract: Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: January 19, 2016
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Majid Vakilynejad
  • Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
    Patent number: 9233103
    Abstract: The present invention relates to methods of treating heartburn in a patient receiving clopidogrel therapy. In another aspect, the present invention relates to methods of preventing gastric bleeding or hemorrhage in patients receiving clopidogrel therapy.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: January 12, 2016
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventor: Ronald D. Lee
  • Methods for concomitant treatment of theophylline and febuxostat
    Patent number: 9107912
    Abstract: The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: August 18, 2015
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Lhanoo Gunawardhana, Max Tsai, Himanshu Naik
  • Methods for treating nephrolithiasis
    Patent number: 8841333
    Abstract: The present invention relates to methods of treating subjects suffering from nephrolithiasis by administering to a subject in need of treatment thereof a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: September 23, 2014
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventor: Nancy Joseph-Ridge
  • Pharmaceutical compositions and methods for treating age-related macular degeneration with melatonin analogues
    Patent number: 8785491
    Abstract: Pharmaceutical compositions and methods for treating and/or preventing age-related macular degeneration with melatonin analogues are provided.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: July 22, 2014
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: David Baron, Keisuke Hirai, Yasushi Shintani, Osamu Uchikawa
  • METHODS FOR ADMINISTRATION OF COLCHICINE WITH GRAPEFRUIT JUICE
    Publication number: 20140107213
    Abstract: Methods for safe administration of colchicine together with consumption of grapefruit juice are disclosed.
    Type: Application
    Filed: October 15, 2013
    Publication date: April 17, 2014
    Applicant: TAKEDA PHARMACEUTICALS U.S.A., INC.
    Inventor: Matthew W. Davis
  • COLCHICINE COMPOSITIONS AND METHODS
    Publication number: 20140037550
    Abstract: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.
    Type: Application
    Filed: October 4, 2013
    Publication date: February 6, 2014
    Applicant: TAKEDA PHARMACEUTICALS U.S.A., INC.
    Inventors: Matthew W. Davis, Shawn G. Watson, Hengsheng FENG
  • Colchicine solid complex; methods of making; and methods of use thereof
    Patent number: 8519002
    Abstract: Disclosed are new colchicine solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: August 27, 2013
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Tong Sun, David Jonaitis, Stephan D. Parent
  • Thiocolchicine derivatives, method of making and methods of use thereof
    Patent number: 8497290
    Abstract: Disclosed herein are thiocolchicine derivatives suitable for use as muscle relaxants, methods of making the derivatives, and compositions comprising the derivatives.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: July 30, 2013
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventor: Rajesh Manchanda
  • METHODS FOR TREATING HYPERTENSION IN BLACK PATIENTS
    Publication number: 20130158080
    Abstract: The present invention relates to methods of treating hypertension in a black patient using a therapeutically effective amount of a combination of an angiotensin II receptor blocker and chlorthalidone.
    Type: Application
    Filed: December 10, 2012
    Publication date: June 20, 2013
    Applicant: Takeda Pharmaceuticals U.S.A., Inc.
    Inventor: Takeda Pharmaceuticals U.S.A., Inc.
  • Multiple PPI dosage form
    Patent number: 8461187
    Abstract: Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
    Type: Grant
    Filed: June 1, 2005
    Date of Patent: June 11, 2013
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Majid Vakilynejad
  • METHODS FOR PRESERVING AND/OR INCREASING RENAL FUNCTION USING XANTHINE OXIDOREDUCTASE INHIBITORS
    Publication number: 20130143886
    Abstract: The present invention relates to methods of preserving or increasing renal function in a subject in need thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. The present invention also relates to methods of increasing renal function in a subject in need thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof.
    Type: Application
    Filed: January 30, 2013
    Publication date: June 6, 2013
    Applicant: Takeda Pharmaceuticals U.S.A., Inc.
    Inventor: Takeda Pharmaceuticals U.S.A., Inc.